The TCM group consists of pure CD4+ MFs, and its signature is associated with an adverse effect on patient survival, suggesting that some CD4+ MF lesions may share a cellular origin with Sézary syndrome and could require more aggressive treatment. This evidence concerns the gene CD4 and Sezary syndrome.